10月8日 - ** 美国药物开发商CervoMed CRVO.O股价在盘前交易中上涨12%至9.55美元
** 该公司表示，其实验性药物neflamapimod在治疗路易体痴呆症（一种常见的老年性痴呆症）的中期试验中显示出良好的效果
** 与安慰剂相比，服用neflamapimod的患者在记忆力和日常功能方面有明显改善 - CRVO
** CRVO称，不太可能患有阿尔茨海默氏症和路易体痴呆症的患者获益最为显著
** 这些结果有助于CRVO完善后期试验计划；该公司预计美国食品药品管理局将在年底前对其后期试验设计提出反馈意见。
** 截至上次收盘，股价上涨 ~265
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.